News articles about China Cord Blood Corporation (NYSE:CO) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. China Cord Blood Corporation earned a news sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 46.9993772277406 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of China Cord Blood Corporation (NYSE CO) opened at $10.97 on Friday. The stock has a market cap of $1,327.85, a price-to-earnings ratio of 37.97 and a beta of 0.95. China Cord Blood Corporation has a 12 month low of $4.27 and a 12 month high of $14.95.

China Cord Blood Corporation (NYSE:CO) last released its quarterly earnings results on Wednesday, August 23rd. The medical research company reported $0.09 earnings per share (EPS) for the quarter. The company had revenue of $33.07 million for the quarter. China Cord Blood Corporation had a net margin of 22.07% and a return on equity of 8.64%.

Separately, BidaskClub raised shares of China Cord Blood Corporation from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 1st.

ILLEGAL ACTIVITY NOTICE: “China Cord Blood Corporation (CO) Getting Somewhat Favorable News Coverage, Study Shows” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at

About China Cord Blood Corporation

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

Insider Buying and Selling by Quarter for China Cord Blood Corporation (NYSE:CO)

Receive News & Ratings for China Cord Blood Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Cord Blood Corporation and related companies with's FREE daily email newsletter.